MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells

DSpace/Manakin Repository

MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells

Citable link to this page

 

 
Title: MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells
Author: Wang, Yubao; Lee, Young-Mi; Baitsch, Lukas; Huang, Alan; Xiang, Yi; Tong, Haoxuan; Lako, Ana; Von, Thanh; Choi, Christine; Lim, Elgene; Min, Junxia; Li, Li; Stegmeier, Frank; Schlegel, Robert; Eck, Michael J; Gray, Nathanael S; Mitchison, Timothy J; Zhao, Jean J

Note: Order does not necessarily reflect citation order of authors.

Citation: Wang, Y., Y. Lee, L. Baitsch, A. Huang, Y. Xiang, H. Tong, A. Lako, et al. 2014. “MELK is an oncogenic kinase essential for mitotic progression in basal-like breast cancer cells.” eLife 3 (1): e01763. doi:10.7554/eLife.01763. http://dx.doi.org/10.7554/eLife.01763.
Full Text & Related Files:
Abstract: Despite marked advances in breast cancer therapy, basal-like breast cancer (BBC), an aggressive subtype of breast cancer usually lacking estrogen and progesterone receptors, remains difficult to treat. In this study, we report the identification of MELK as a novel oncogenic kinase from an in vivo tumorigenesis screen using a kinome-wide open reading frames (ORFs) library. Analysis of clinical data reveals a high level of MELK overexpression in BBC, a feature that is largely dependent on FoxM1, a master mitotic transcription factor that is also found to be highly overexpressed in BBC. Ablation of MELK selectively impairs proliferation of basal-like, but not luminal breast cancer cells both in vitro and in vivo. Mechanistically, depletion of MELK in BBC cells induces caspase-dependent cell death, preceded by defective mitosis. Finally, we find that Melk is not required for mouse development and physiology. Together, these data indicate that MELK is a normally non-essential kinase, but is critical for BBC and thus represents a promising selective therapeutic target for the most aggressive subtype of breast cancer. DOI: http://dx.doi.org/10.7554/eLife.01763.001
Published Version: doi:10.7554/eLife.01763
Other Sources: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4059381/pdf/
Terms of Use: This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAA
Citable link to this page: http://nrs.harvard.edu/urn-3:HUL.InstRepos:12406532
Downloads of this work:

Show full Dublin Core record

This item appears in the following Collection(s)

 
 

Search DASH


Advanced Search
 
 

Submitters